RxDoctor Payments Data

Jose Carlo Izquierdo, MD

Pain Medicine · San Juan, PRNPI 1710023668

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $31,419 of the $49,153 with a category attached, or 63.9%. 23 manufacturers reported payments, led by Amgen at 41.8% of the total. 2025 is the largest year on record at $37,194, more than ten times the $2,332 reported in 2019. Among pain medicine clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$49,153in general payments, 2019–2025

Across 143 payments — averaging $343.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$21K
  • Argenx US, Inc.$16K
  • Sanofi$10K
  • AstraZeneca$697
  • Biogen$681
  • Novartis$238
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$8,40317%
  • Speaking & faculty fees$31,41964%
  • Travel & lodging$4,97710%
  • Food & beverage$4,2139%
  • Education$1420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,153 in reported general payments places this provider in the 90th percentile of 46 pain medicine providers in Puerto Rico.

See all pain medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$29,636
Medicare patients
101
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone15$212,128
Pyridostigmine Bromide44$3,993
Gabapentin169$3,035
Carbidopa-Levodopa ErCarbidopa/Levodopa13$3,034
Rivastigmine14$1,984
SynthroidLevothyroxine Sodium18$1,158
Carbidopa-LevodopaCarbidopa/Levodopa26$900
Pregabalin62$744
ValacyclovirValacyclovir Hcl11$623
Donepezil Hcl54$610
Memantine Hcl20$552
Prednisone56$467
Quetiapine Fumarate35$427
Clonazepam36$400
Oxcarbazepine22$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$74$1,15818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 46 pain medicine providers in Puerto Rico.

Other pain medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →